Name change reflects company's leadership position with its cryptocurrency treasury reserve strategy focused on the HYPE token Company to commence trading on Nasdaq under the symbol "HYPD" effective July 3rd Also announces official launch of the Kinetiq x Hyperion validator LAGUNA HILLS, Calif., July 02, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) ("Eyenovia" or the "Company"), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, t ...

LAGUNA HILLS, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) ("Eyenovia" or the "Company"), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyperliquid protocol, today announced that it has acquired an additional 265,872 HYPE tokens, expanding its total holdings to 1,306,452 HYPE purchased at an average price of $34.83 per token. HYPE is the native token of Hyperliquid. Staked HYPE in part ...

The validator marks a significant step in Eyenovia's onchain engagement strategy, utilizing its recent acquisition of 1,040,584.5 HYPE to contribute directly to network stability and security. Validator operations are further supported by infrastructure provided by Pier Two, an institutional staking services provider known for its high-performance hybrid cloud and bare metal infrastructure complete with both SOC 2 Type I and Type II certifications. "Our collaboration with Kinetiq and Pier Two marks a strate ...

Core Insights - Eyenovia, Inc. is advancing its digital asset capital strategy by building a strategic treasury of HYPE, the native token of the Hyperliquid protocol [1][7] - Avenue Capital Group has become the largest common stockholder and has amended Eyenovia's senior secured debt to support the HYPE treasury, extending the maturity date to July 1, 2028, and reducing the interest rate from 12% to 8% [2] - Max Fiege has been appointed as Strategic Advisor to enhance the HYPE Treasury strategy, focusing on stakeholder education and ecosystem advocacy [4] Financial Developments - The amendment to the debt includes interest-only payments for the first 18 months, followed by equal principal and interest payments for the next 18 months [2] - The reduced interest rate and extended maturity are expected to provide financial flexibility as the company builds its HYPE treasury [2] Strategic Appointments - Max Fiege, with a background in blockchain and digital assets, will assist in the treasury architecture and risk oversight for Eyenovia [4][5] - His expertise is anticipated to enhance the company's position in the digital finance landscape [5] HYPE Token Overview - HYPE is the native token of the Hyperliquid layer one blockchain, allowing for non-custodial trading and offering utility such as trading fee discounts [6] - As of June 2025, HYPE ranks as the 12th-largest cryptocurrency by market capitalization [6] Company Overview - Eyenovia is a pioneering digital ophthalmic technology company, focusing on both innovative eye treatment solutions and building a treasury of HYPE [7] - The company is also developing the Optejet User Filled Device, targeting multiple billion-dollar markets in ophthalmic treatments [8]

Core Insights - RetinalGenix Technologies Inc. has appointed Dr. Taimour Langaee as a scientific advisor to enhance its DNA GPS Pharmacogenetics initiatives aimed at optimizing personalized treatment pathways for retinal and systemic diseases [1][5] - Dr. Langaee brings over 20 years of experience in pharmacogenomics and precision medicine, overseeing genotyping, sequencing data processing, and clinical genetic association studies [2][3] - The company aims to integrate advanced retinal imaging with pharmacogenetics and AI to identify early signs of chronic diseases, thereby improving overall health management and reducing long-term healthcare costs [6][7] Company Overview - RetinalGenix is focused on revolutionizing early disease detection and improving patient outcomes by combining genetic screening, advanced imaging, and therapeutic development [9] - The company's proprietary technologies include High-Resolution Retinal Imaging and DNA/RNA/GPS Pharmaco-Genetic Mapping™, which are designed to prevent blindness and detect physiological changes indicating future ocular and systemic diseases [9] Strategic Goals - The integration of Dr. Langaee's expertise is expected to accelerate the company's efforts in delivering personalized, data-driven solutions for retinal and systemic health [5] - RetinalGenix's approach includes remote monitoring and personalized risk assessments based on genetic profiles, which aims to maximize the effectiveness of preventive strategies [7][8]

Glaukos (GKOS) Q1 2025 Earnings Call April 30, 2025 04:30 PM ET Speaker0 Welcome to the Glycos Corporation First Quarter twenty twenty five Financial Results Conference Call. Copies of the company's press release and quarterly summary document, both issued after the market closed today, are available at www.glycos.com. As a reminder, all lines are muted until the end of today's presentation, where we will have a question and answer session. This call is being recorded and an archived replay will be made ava ...

RESEARCH TRIANGLE PARK, N.C., March 21, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and therapies for other ophthalmic disorders, today announced that a presentation featuring the LYNX-1 Phase 3 study of Phentolamine Ophthalmic Solution 0.75% in patients with dim light disturbances will be delivered this week at World Cornea Congress IX, taking place March 20-22, ...

Additional approximately $21 million tied to data release for the Company’s BEST1 programRESEARCH TRIANGLE PARK, N.C., March 21, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (“Opus” or the “Company”) (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and therapies for other ophthalmic disorders, today announced the pricing of an underwritten public offering with gross proceeds of $20 million and concurrent private ...